Recent weeks have seen Indian generics giant Lupin Limited receive numerous approvals from the US Food and Drug Administration. Since the release of its financial results for the second quarter of its 2024 financial year at the beginning of November, Lupin has received five approvals for generic drugs.
Key takeaways:
-
Recent weeks have seen Lupin secure approvals from the US Food and Drug Administration for five generic drugs: bromfenac ophthalmic solution, ganirelix acetate injection, pitavastatin tablets, dapagliflozin and canagliflozin
-
The firm has also partnered with Amman Pharmaceutical Industries to market its biosimilar ranibizumab across the Middle East, and launched the novel Vilfuro-G (vilanterol, fluticasone furoate and glycopyrronium bromide) in India
-
These announcements come
Particularly significant is the approval of its abbreviated new drug application to market a generic version of Bausch & Lomb’s Prolensa (bromfenac ophthalmic solution)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?